Pyridyl sulfone derivatives

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I:

• wherein
• W1-W3 are —C(R) or N with the proviso that no more than one of W1-W3 are nitrogen, and further provided that when W2 is N that W3 is not —C(CN);
• A is a phenyl or naphthyl ring, a five or six-membered heteroaryl ring, a eight to ten-membered fused heteroaryl ring, the five or six membered monocyclic heteroaryl ring and the eight or ten membered fused heteroaryl ring system each optionally containing up to three heteroatoms (O, N, S);
• or a nine membered fused heteroaryl ring system containing one to three heteroatoms (O, N, S);
• each of the five- or six-membered monocyclic heteroaryl ring and the eight- to ten-membered ring systems being optionally substituted with 1-4 of R;
• Each R is independently selected from H, halo, alkyl, cycloalkyl, substituted alkyl, —OH, alkoxy, substituted alkoxy, —SH, —S-alkyl, —S-substituted alkyl, —CN, —NO2, —NR1R2, —NR1SO2-alkyl, —NR1SO2-aryl, —COOR3, —CONR1R2, —SO2NR1R2, —SO2—alkyl, het, substituted het, aryl and substituted aryl;
• G is
• Each R1 and R2 is independently H, alkyl, cycloalkyl, substituted alkyl, aryl, het, substituted aryl, and substituted het, or R1 and R2 when taken together form a five, six, or seven-membered ring which optionally contains a heteroatom selected from N, O, or S;
• Each R3 is independently H, alkyl, cycloalkyl, or substituted alkyl;
• Each R7 is independently H or alkyl, or oxo provided that R8 is absent when the oxo moiety is bound to the same carbon;
• Each R8 is independently H or alkyl;
• Each R9 and R10 is independently H, alkyl, or substituted alkyl;
• wherein
• cycloalkyl is a cyclic alkyl moiety have between 3 and 7 carbon atoms;
• substituted alkyl is an alkyl moiety including 1-4 substituents selected from halo, cycloalkyl, cycloalkenyl, heterocycloalkyl, het, aryl, —OQ10, —SQ10, —S(O)2Q10, —S(O)Q10, —OS(O)2Q10, —C(═NQ10)Q10, SC(O)Q10, —NQ10Q10, —C(O)Q10, —C(S)Q10, —C(O)OQ10, —OC(O)Q10, —C(O)NQ10Q10, —C(O)C(Q16)2OC(O)Q10, —CN, ═O, ═S, —NQ10C(O)Q10, —NQ10C(O)NQ10Q10, —S(O)2NQ10Q10, —NQ10S(O)2Q10, —NQ10S(O)Q10, and —NO;
• substituted alkoxy is an alkoxy moiety including 1-3 substituents —OQ10, —SQ10, —S(O)2Q10, —S(O) Q10, —OS(O)2Q10, —C(═NQ10)Q10, —SC(O)Q10, —NQ10Q10, —C(O)Q10, —C(S)Q10, —C(O)OQ10, —OC(O)Q10, —C(O)NQ10Q10, —C(O)C(Q16)2OC(O)Q10, —CN, ═O, ═S, —NQ10C(O)Q10, —NQ10C(O)NQ10Q10, —S(O)2NQ10Q10, —NQ10S(O)2Q10, —NQ10S(O)Q10, —NO2, alkyl, substituted alkyl, halo, cycloalkyl, heterocycloalkyl, het, aryl, and cycloalkenyl;
• het is a C-linked five-(5) membered heteroaryl ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen;
• a C-linked six (6) membered heteroaryl ring having a 1-3 nitrogen atoms;
• a eight (8) membered bicyclic heteroaryl ring system having 1-3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen;
• and a ten (10) membered bicyclic heteroaryl ring system having 1-3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen;
• substituted het is a het moiety having 1-3 substituents selected from —OQ10, —SQ10, —S(O)2Q10, —S(O)Q10, —OS(O)2Q10, —C(═NQ10)Q10, —SC(O)Q10, —NQ10Q10, —C(O)Q10, —C(S)Q10, —C(O)OQ10, —OC(O)Q10, —C(O)NQ10Q10, —C(O)C(Q16)2OC(O)Q10, —CN, —NQ10C(O)Q10, —NQ10C(O)NQ10Q10, —S(O)2NQ10Q10, —NQ10S(O)2Q10, —NQ10S(O)Q10, —NO2, alkyl, substituted alkyl, halo, cycloalkyl, cycloalkenyl heterocycloalkyl, het, and aryl;
• wherein heterocycloalkyl is a cyclic alkyl moiety having between 5 and 7 ring atoms, including 1-4 heteroatoms in the ring selected from the group consisting of oxygen, sulfur and nitrogen;
• wherein Q10, Q11, Q14, Q15, and Q16 are as defined in the specification;
• n is 0-1;
• any racemic, optically active, tautomeric, stereoisomeric form, mixtures or pharmaceutically acceptable salt thereof;
• and
• a pharmaceutically acceptable carrier.